Zobrazeno 1 - 10 of 1 964 pro vyhledávání: '"Buluwela, L."'
1
Akademický článek
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
Autor: Gemma C; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Lai CF; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Singh AK; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Belfiore A; Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; School of Medicine, University of Milan, Milan, Italy., Portman N; Garvan Institute of Medical Research, Darlinghurst, Australia., Milioli HZ; Garvan Institute of Medical Research, Darlinghurst, Australia., Periyasamy M; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Raafat S; Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.; Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Nottingham, United Kingdom., Nicholls AJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Davies CM; Department of Surgery and Cancer, ECMC Imperial College, Imperial College London, Hammersmith Campus, London, United Kingdom., Patel NR; Department of Surgery and Cancer, ECMC Imperial College, Imperial College London, Hammersmith Campus, London, United Kingdom., Simmons GM; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Fan H; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Nguyen VTM; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Magnani L; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Rakha E; Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.; Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Nottingham, United Kingdom., Martin LA; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom., Lim E; Garvan Institute of Medical Research, Darlinghurst, Australia.; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia., Coombes RC; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Pruneri G; Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; School of Medicine, University of Milan, Milan, Italy., Buluwela L; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom., Ali S; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom.
Publikováno v: Cancer research [Cancer Res] 2024 Dec 16; Vol. 84 (24), pp. 4283-4297.
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
CDK7 inhibitors as anticancer drugs.
Autor: Sava GP; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Fan H; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Coombes RC; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Buluwela L; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Ali S; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK. simak.ali@imperial.ac.uk.
Publikováno v: Cancer metastasis reviews [Cancer Metastasis Rev] 2020 Sep; Vol. 39 (3), pp. 805-823.
Zobrazit plný text záznamu
5
Akademický článek
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Autor: Harrod A; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.; Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK., Lai CF; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Goldsbrough I; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Simmons GM; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Oppermans N; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Santos DB; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Győrffy B; Semmelweis University Department of Bioinformatics, H-1094 Budapest, Hungary and TTK Cancer Biomarker Research Group, H-1117, Budapest, Hungary., Allsopp RC; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK., Toghill BJ; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK., Balachandran K; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Lawson M; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK., Morrow CJ; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK., Surakala M; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK., Carnevalli LS; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK., Zhang P; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK., Guttery DS; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK., Shaw JA; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK., Coombes RC; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK., Buluwela L; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK. l.buluwela@imperial.ac.uk., Ali S; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK. simak.ali@imperial.ac.uk.
Publikováno v: Oncogene [Oncogene] 2022 Oct; Vol. 41 (44), pp. 4905-4915. Date of Electronic Publication: 2022 Oct 05.
Zobrazit plný text záznamu
6
Akademický článek
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Autor: Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., McGinn O; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., Wu Y; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA.; School of Medicine, Tsinghua University, Beijing, China., Bahreini A; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Priedigkeit NM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., Ding K; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., Onkar S; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA.; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lampenfeld C; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Sartorius CA; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Miller L; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., Rosenzweig M; School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA., Cohen O; Department of Medical Oncology and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Wagle N; Department of Medical Oncology and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Richer JK; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Muller WJ; Goodman Cancer Centre and Departments of Biochemistry and Medicine, McGill University, Montreal, QC, Canada., Buluwela L; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Ali S; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK., Bruno TC; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Vignali DAA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Fang Y; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Zhu L; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Tseng GC; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Gertz J; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Atkinson JM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA., Lee AV; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. oesterreichs@upmc.edu.; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. oesterreichs@upmc.edu.; Magee-Womens Research Institute, Pittsburgh, PA, USA. oesterreichs@upmc.edu.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA. oesterreichs@upmc.edu.
Publikováno v: Nature communications [Nat Commun] 2022 Apr 19; Vol. 13 (1), pp. 2011. Date of Electronic Publication: 2022 Apr 19.
Zobrazit plný text záznamu
7
Akademický článek
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Autor: Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Wu Y; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; School of Medicine, Tsinghua University, Beijing, P.R. China., Yates ME; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, Pennsylvania.; Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Tasdemir N; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Bahreini A; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania., Chen J; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Levine KM; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Priedigkeit NM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Nasrazadani A; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Ali S; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Buluwela L; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Arnesen S; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Gertz J; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Richer JK; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Troness B; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota., El-Ashry D; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota., Zhang Q; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois., Gerratana L; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois.; Department of Medicine (DAME) University of Udine, Udine, Italy., Zhang Y; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois., Cristofanilli M; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois., Montanez MA; Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Sundd P; Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Wallace CT; Center for Biological Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania., Watkins SC; Center for Biological Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania., Fumagalli C; Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Guerini-Rocco E; Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Zhu L; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Tseng GC; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Wagle N; Department of Medical Oncology and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts., Carroll JS; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Jank P; Institut of Pathology, Philipps-University Marburg, UKGM - Universitätsklinikum Marburg, Marburg, Germany., Denkert C; Institut of Pathology, Philipps-University Marburg, UKGM - Universitätsklinikum Marburg, Marburg, Germany., Karsten MM; Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humbold-Univeristät zu Berlin and Berlin Institute of Health, Berlin, Germany., Blohmer JU; Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humbold-Univeristät zu Berlin and Berlin Institute of Health, Berlin, Germany., Park BH; Vanderbilt University Ingraham Cancer Center, Nashville, Tennessee., Lucas PC; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Atkinson JM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Lee AV; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania., Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Publikováno v: Cancer research [Cancer Res] 2022 Apr 01; Vol. 82 (7), pp. 1321-1339.
Zobrazit plný text záznamu
10
Akademický článek
Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.
Autor: Mayayo-Peralta I; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Faggion B; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Morris B; Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Lieftink C; Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Goldsbrough I; Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK., Buluwela L; Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK., Siefert JC; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Post H; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands., Beijersbergen R; Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Ali S; Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK., Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands., Prekovic S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Publikováno v: Cancers [Cancers (Basel)] 2021 Dec 16; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 16.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje